Clinical Trial Update: Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy, safety, and tolerability of ACT-129968 in seasonal allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• ACT-129968

Snippet

Sponsor: Idorsia Pharmaceuticals Ltd. | Conditions: Seasonal Allergic Rhinitis | Phase 3 | Status: COMPLETED